Does a second diagnosis automatically exclude you?
Read the published criteria as questions to clarify, not as a personal verdict. Some studies focus narrowly on one condition, while others consider combinations or a broader range of experiences. A short listing may not explain every relevant detail or exception, and it cannot confirm your eligibility. Ask the team about the particular combination you want to discuss through its verified private process. Neither a diagnosis label nor a directory filter establishes acceptance or exclusion on its own. Keep the study identifier so the team can answer about the correct protocol.
Why does the team ask about other conditions?
The study question, interpretation of results and participant safety can make other health conditions relevant to assessment. That is a property of the research design, not a measure of your worth or whether you deserve care. Ask which conditions matter for this protocol and why. Distinguish a diagnosis in your records from current symptoms and from the treatment you receive. Physical health, sleep, substance use or other care may also be relevant when the team asks about them. You should not need to guess the reasoning behind a criterion.
Which information should you share, and where?
Ask what is needed for an initial enquiry and what belongs in a later screening discussion. A medicine list, relevant health history and current care arrangements may help, depending on the study. Do not post personal details in public comments or send records to an unverified contact. Ask how the centre receives sensitive information and whether it needs documents from your clinicians. Give an accurate account through that process. You can ask the purpose of a question and explain when you do not know the answer.
What if a diagnosis is uncertain or has changed?
You can describe what a clinician told you, when it was discussed and what remains uncertain, without trying to resolve it yourself for the application. Ask whether the team needs a record, an updated assessment or clarification from a treating clinician. A research eligibility assessment should not be treated as a diagnosis from a general website. If older paperwork and your current understanding differ, raise the difference. Do not choose whichever label seems most likely to secure a place or conceal a history that the team needs to assess safely.
Do medicines or stability requirements affect the answer?
They may, depending on the protocol, but do not change medication, therapy or follow-up to appear eligible. Ask whether your present treatment is compatible and what the study would require if you were otherwise suitable. If any change is proposed, discuss its purpose, risks, monitoring and alternatives with the research clinician and your usual clinician. A study’s definition of stability is not a personal judgment or a general treatment target. Ask the team to explain the criterion rather than interpreting a brief label on your own.
What can you do if this study is unsuitable?
Ask whether the decision concerns one criterion, a missing record, the study’s design or a practical constraint, if you want an explanation. You can ask about other types of research without assuming an alternative place exists. Keep usual care in place while exploring options. An optional first message is: “I am interested in study [identifier]. Could you explain how co-occurring conditions are assessed and where I can share relevant details privately?” Replace the identifier, not the private details, before using a general contact route. The answer may help you decide whether to pursue screening.